Post by CampGreyhound on Oct 2, 2010 15:15:38 GMT -5
From Brigham University, back in 2002:
www.prweb.com/releases/2002/03/prweb34782.htm
Humanitarian Aid: ...Colloidal silver as an antibiotic alternative, for use in its hospitals and water treatment units in Africa, South America, and Asia.
American Silvers Antibacterial Product (PRWEB) March 9, 2002
The following results suggest that The NEW Silver Solution is a broad spectrum antimicrobial agent -- it is able to effectively stop the growth of, and in fact kill, a variety of bacteria.
The NEW Silver Solution has been tested against the following organisms.
Tuberculosis type B (tuberculosis is the number one human-killing bacteria world wide)
Staphylococcus aureus (Pneumonia, eye infections, skin infections (boils, impetigo, cellulitis, and post-operative wound infections), toxic shock syndrome, meningitis, food poisoning, osteomyelitis, and many others) inhibited @ 2.5 ppm[c][12] and killed @ 5 ppm. 1/22/99 BYU Report.
Shigella boydii (Bacillary dysentery--characterized by severe cramping abdominal pain and bloody diarrhea) inhibited @ 1.25 ppm and killed @ 2.5 ppm. 1/22/99 BYU Report.
Salmonella arizona (Food poisoning, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/28/99 BYU Report.
Salmonella typhimurium (Food poisoning and enteric fever) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
E. coli (Food poisoning, urinary tract infections, travelers diarrhea, diarrhea in infants, respiratory tract infections, and wound infections) inhibited and killed @ 2.5 ppm. 1/22/99 BYU Report.
Haemophilus influenzae (Otitis media (ear infection), pneumonia, meningitis, throat and sinus infections (including epiglottitis in children and sinusitis), and suppurative arthritis in children) inhibited and killed @ 1.25 ppm. 1/22/99 BYU Report.
Enterobacter aerogenes ( wound infections, urinary tract infections, bacteremia, and meningitis) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
Enterobacter cloacae ( causes ilnesses similar to the E. aerogenes) inhibited and killed at a concentration of 5 ppm. 6/7/99 BYU Report.
Klebsiella pneumoniae (lower respiratory tract infections, nosocomial infections (infections spread in hospitals), urinary tract and wound infections, and bacteremia) inhibited and killed @ 2.5 ppm. 1/28/99 BYU Report.
Klebsiella oxytoca, (Similar to those infections caused by K. pneumoniae) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
Pseudomonas aeruginosa (severe burn and wound infections, keratitis, pneumonia, meningitis, nosocomial infections, urinary tract infections, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.
Streptococcus pneumoniae (pneumonia, meningitis, sinusitis, otitis media (ear infection) inhibited @ 2.5 ppm and killed @ 5 ppm. 4/21/99 BYU Report.
Streptococcus pyogenes (skin infections, upper respiratory infections (i.e. strep throat) impetigo, hospital-acquired infections, scarlet fever, etc.) inhibited and killed @ 1.25 ppm. 1/22/99 BYU Report.
Streptococcus faecalis (Urinary tract infections, endocarditis, wound infections, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.
Streptococcus mutans (A major cause dental plaque and tooth decay etc.) inhibited and killed @ 5 ppm. 2/3/99 BYU Report.
Streptococcus gordonii (Tooth decay, also implicated in infective endocarditis-an infection of the heart valves) inhibited and killed @ 5 ppm. BYU Report 2/12/99 .
David A. Revelli
Microbiologist
Brigham Young University
Dr. Ron W. Leavitt , Ph.D.
Professor of Microbiology/Molecular Biology
Brigham Young University
www.coralconnection.net/cgi-bin/ ... 333005221/
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
From Medline:http://www.medscape.com/viewarticle/545270_1
Regarding the topical use of silver for bone infections.
The Use of Silver-Impregnated Packing Strips in the Treatment of Osteomyelitis: A Case Report
Michael F. Moore, MD, FACS, CWS; Nanci Dobson, RN; Jeffrey T. Glattly, BBA
Authors and Disclosures
Posted: 10/18/2006; Wounds. 2006;18(9):271-276. © 2006 Health Management Publications, Inc.
Information from Industry
Excellent Efficacy for OAB Drug Treatment
The unique combination of benefits provided by this OAB drug therapy provides excellent efficacy.
Review the data
Abstract and Introduction
Abstract
The treatment of osteomyelitis is multifactorial and requires surgical debridement of the infected bone as well as the use of systemic antimicrobials for an extended period of time. Traditionally, these wounds are packed open to allow healing by secondary intent, and the dressing has only a passive action. The case reported here employs the use of an interactive silver packing strip that facilitated healing because of its antimicrobial activity for which the authors believe further evaluation is justified.
Introduction
The incidence of neurotropic ulcers is reported to affect between 4% and 6% of the diabetic population and is associated with significant morbidity.[1] It has been reported that 85% of lower leg amputations initially present as a foot ulceration.[1] Complicating the initial clinical presentation of the ulcer is the extent and degree of pathology involved. The sensory deprivation and lack of pain associated with these ulcers causes the initial clinical presentation to include significant tissue necrosis requiring extensive surgical intervention. Deep-seated abscesses with extensive undermining and osteomyelitis often accompany the small ulceration that initially brings the patient to seek medical attention. The diminished immune response found in the diabetic population also factors into the degree of pathology associated with these ulcers.
The diagnosis of osteomyelitis is problematic with these ulcers. Though it is suspected clinically when probing to bone is present, the classical radiographic findings often lag behind the clinical picture. Additionally, the use of systemic antimicrobials can be ineffectual in achieving suitable levels at the ulcer site.[2] The polymicrobial flora that is often present in the chronic wound may limit the use of topical antimicrobial agents because of the lack of sensitivity, potential toxicity to the host cellular components, and the potential for the development of resistant strains.[3]
The use of topical silver dressings has expanded in the chronic wound care setting due to the broad antimicrobial spectrum, low toxicity, and resistance profile of silver.[4] The recent introduction of silver-impregnated wound packing strips (SilverSeal® packing strips with X-Static®, Noble Biomaterials, Scranton, Pa) affords the clinician the ability to deliver the antimicrobial effect of silver using recommended treatment protocols.[5] Silver-impregnated packing strips are similar to existing packing products on the market in that they come in varying widths (Figure 1) to accommodate diverse clinical presentations. Unlike standard gauze, the strips are manufactured using nylon fiber that has been metalized with pure silver (Figures 2 and 3). The nylon resists absorption of wound fluid, enhancing the wicking effect and allowing the metalized silver fiber greater surface area to interact in the wound environment. The hydrophobic effect of the nylon fiber prevents saturation of the dressing, allowing it to function over longer periods of time, thereby decreasing dressing changes. The following case presentation represents the clinical use of this modality, resulting in resolution of the patient's ulcer in a shorter period of time than the usual 6 weeks stipulated for such treatment.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
_________________
Alpha
Visit Camp Greyhound at Awesomepaws!
Visit our Webstore
Offline
Profile
Alpha
Post subject: Re: Research on Colloidal Silver
PostPosted: Sat Feb 06, 2010 10:21 pm
Site Admin
Joined: Sun Jan 03, 2010 1:07 pm
Posts: 91
Location: Innisfil
Study Title:
Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia
Silver is the key to reducing pneumonia associated with breathing tubes. From Journal of the American Medical Association, Aug. 20, 2008. Full study at:
www.wellnessresources.com/studie ... _infection
People have long prized silver as a precious metal. Now, silver-coated endotracheal tubes are giving critically ill patients another reason to value the lustrous metal. In a study published in the Aug. 20, 2008 issue of the Journal of the American Medical Association, researchers at Washington University School of Medicine in St. Louis and the NASCENT Investigation Group, report that the silver-coated tubes led to a 36 percent reduction of ventilator-associated pneumonia (VAP).
VAP can strike up to 15 percent of people who are intubated to aid breathing and can cause death in an estimated 20 percent to 40 percent of those stricken.
“VAP is a relatively common infection and increasingly one caused by antibiotic-resistant bacteria,” says the study’s lead author, Marin H. Kollef, M.D., a Washington University pulmonary specialist at Barnes-Jewish Hospital. “There have been many attempts to prevent VAP, most of which have revolved around modifying hospital practices. The silver-coated endotracheal tube has an advantage in that it doesn’t require any additional effort by nurses, therapists and doctors, who may already be over burdened.”
Past efforts to prevent VAP included elevating the head of a patient’s bed, repeatedly checking ventilator tubing and emptying condensates, monitoring feeding to prevent reflux into the lungs, frequent handwashing and isolation of infected patients. The silver-coated endotracheal tube is structurally identical to a typical tube, so its adoption would not require any change in standard hospital procedures.
Studying 1,509 patients in 54 centers who were intubated for 24 hours or more, the research group found that 7.5 percent of those with uncoated tubes developed VAP. In comparison, 4.8 percent of those with silver-coated tubes developed VAP, a 36 percent reduction.
Kollef indicates that about 80 percent of patients are intubated for less than 10 days. Looking at just the first 10 days of intubation, the silver-coated tubes were associated with a 48 percent reduction in VAP, and when VAP occurred in patients with silver-coated tubes, it occurred later on average than in those with uncoated tubes.
Silver kills bacteria and yeast by sticking to the organisms’ enzymes, genetic material and other molecular components, preventing basic functions and interfering with reproduction. These organisms very rarely develop resistance to silver, and the metal has no known side effects in humans.
The new endotracheal tubes are coated with a silver-containing polymer, created by C.R. Bard Inc., that releases silver ions to the surface of the tubes. There, silver exerts a broad-spectrum antimicrobial effect, reduces adhesion of bacteria to the tube and blocks the formation of biofilms, communities of microorganisms that build up special protective structures on surfaces.
The number of antibiotic-resistant organisms is on the rise, making it ever more vital to prevent VAP and related infections, says Kollef, professor of medicine in the Division of Pulmonary and Critical Care Medicine. Even when an infection can be treated with antibiotics, it takes a physical toll on a patient, he notes.
Kollef, also medical director of the medical intensive care unit and of respiratory care services at Barnes-Jewish Hospital, says the silver-coated tubes are likely to be more expensive than uncoated tubes, but that the cost is easily recovered if the silver-coated tubes can reduce the number of VAP cases.
“I think this is just the beginning for this kind of technology,” Kollef says. “The silver-polymer coating will most likely be applied also to tracheostomy tubes and also become available for use in pediatric medicine. In the future, we could see other types of coatings with other functions placed on devices that come into contact with the body.”
###
Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Craven DE, Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI, Auger WR, Schinner R. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia. Journal of the American Medical Association, Aug. 20, 2008.
Funding from C.R. Bard Inc. supported this research. None of the study authors is associated with C.R. Bard Inc. Marin Kollef received speaker fees from the company.
NASCENT is the North American Silver-Coated Endotracheal Tube Investigation Group, which includes members at 11 institutions in the United States and one in Germany.
Study Information:
Marin H. Kollef, MD; Bekele Afessa, MD; Antonio Anzueto, MD; Christopher Veremakis, MD; Kim M. Kerr, MD; Benjamin D. Margolis, MD; Donald E. Craven, MD; Pamela R. Roberts, MD; Alejandro C. Arroliga, MD; Rolf D. Hubmayr, MD; Marcos I. Restrepo, MD; William Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia JAMA 2008 August 300(7):805-813.
Washington University School of Medicine, St Louis, Missouri.
www.prweb.com/releases/2002/03/prweb34782.htm
Humanitarian Aid: ...Colloidal silver as an antibiotic alternative, for use in its hospitals and water treatment units in Africa, South America, and Asia.
American Silvers Antibacterial Product (PRWEB) March 9, 2002
The following results suggest that The NEW Silver Solution is a broad spectrum antimicrobial agent -- it is able to effectively stop the growth of, and in fact kill, a variety of bacteria.
The NEW Silver Solution has been tested against the following organisms.
Tuberculosis type B (tuberculosis is the number one human-killing bacteria world wide)
Staphylococcus aureus (Pneumonia, eye infections, skin infections (boils, impetigo, cellulitis, and post-operative wound infections), toxic shock syndrome, meningitis, food poisoning, osteomyelitis, and many others) inhibited @ 2.5 ppm[c][12] and killed @ 5 ppm. 1/22/99 BYU Report.
Shigella boydii (Bacillary dysentery--characterized by severe cramping abdominal pain and bloody diarrhea) inhibited @ 1.25 ppm and killed @ 2.5 ppm. 1/22/99 BYU Report.
Salmonella arizona (Food poisoning, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/28/99 BYU Report.
Salmonella typhimurium (Food poisoning and enteric fever) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
E. coli (Food poisoning, urinary tract infections, travelers diarrhea, diarrhea in infants, respiratory tract infections, and wound infections) inhibited and killed @ 2.5 ppm. 1/22/99 BYU Report.
Haemophilus influenzae (Otitis media (ear infection), pneumonia, meningitis, throat and sinus infections (including epiglottitis in children and sinusitis), and suppurative arthritis in children) inhibited and killed @ 1.25 ppm. 1/22/99 BYU Report.
Enterobacter aerogenes ( wound infections, urinary tract infections, bacteremia, and meningitis) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
Enterobacter cloacae ( causes ilnesses similar to the E. aerogenes) inhibited and killed at a concentration of 5 ppm. 6/7/99 BYU Report.
Klebsiella pneumoniae (lower respiratory tract infections, nosocomial infections (infections spread in hospitals), urinary tract and wound infections, and bacteremia) inhibited and killed @ 2.5 ppm. 1/28/99 BYU Report.
Klebsiella oxytoca, (Similar to those infections caused by K. pneumoniae) inhibited and killed at a concentration of 2.5 ppm. 6/7/99 BYU Report.
Pseudomonas aeruginosa (severe burn and wound infections, keratitis, pneumonia, meningitis, nosocomial infections, urinary tract infections, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.
Streptococcus pneumoniae (pneumonia, meningitis, sinusitis, otitis media (ear infection) inhibited @ 2.5 ppm and killed @ 5 ppm. 4/21/99 BYU Report.
Streptococcus pyogenes (skin infections, upper respiratory infections (i.e. strep throat) impetigo, hospital-acquired infections, scarlet fever, etc.) inhibited and killed @ 1.25 ppm. 1/22/99 BYU Report.
Streptococcus faecalis (Urinary tract infections, endocarditis, wound infections, etc.) inhibited @ 2.5 ppm and killed @ 5 ppm. 1/22/99 BYU Report.
Streptococcus mutans (A major cause dental plaque and tooth decay etc.) inhibited and killed @ 5 ppm. 2/3/99 BYU Report.
Streptococcus gordonii (Tooth decay, also implicated in infective endocarditis-an infection of the heart valves) inhibited and killed @ 5 ppm. BYU Report 2/12/99 .
David A. Revelli
Microbiologist
Brigham Young University
Dr. Ron W. Leavitt , Ph.D.
Professor of Microbiology/Molecular Biology
Brigham Young University
www.coralconnection.net/cgi-bin/ ... 333005221/
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
From Medline:http://www.medscape.com/viewarticle/545270_1
Regarding the topical use of silver for bone infections.
The Use of Silver-Impregnated Packing Strips in the Treatment of Osteomyelitis: A Case Report
Michael F. Moore, MD, FACS, CWS; Nanci Dobson, RN; Jeffrey T. Glattly, BBA
Authors and Disclosures
Posted: 10/18/2006; Wounds. 2006;18(9):271-276. © 2006 Health Management Publications, Inc.
Information from Industry
Excellent Efficacy for OAB Drug Treatment
The unique combination of benefits provided by this OAB drug therapy provides excellent efficacy.
Review the data
Abstract and Introduction
Abstract
The treatment of osteomyelitis is multifactorial and requires surgical debridement of the infected bone as well as the use of systemic antimicrobials for an extended period of time. Traditionally, these wounds are packed open to allow healing by secondary intent, and the dressing has only a passive action. The case reported here employs the use of an interactive silver packing strip that facilitated healing because of its antimicrobial activity for which the authors believe further evaluation is justified.
Introduction
The incidence of neurotropic ulcers is reported to affect between 4% and 6% of the diabetic population and is associated with significant morbidity.[1] It has been reported that 85% of lower leg amputations initially present as a foot ulceration.[1] Complicating the initial clinical presentation of the ulcer is the extent and degree of pathology involved. The sensory deprivation and lack of pain associated with these ulcers causes the initial clinical presentation to include significant tissue necrosis requiring extensive surgical intervention. Deep-seated abscesses with extensive undermining and osteomyelitis often accompany the small ulceration that initially brings the patient to seek medical attention. The diminished immune response found in the diabetic population also factors into the degree of pathology associated with these ulcers.
The diagnosis of osteomyelitis is problematic with these ulcers. Though it is suspected clinically when probing to bone is present, the classical radiographic findings often lag behind the clinical picture. Additionally, the use of systemic antimicrobials can be ineffectual in achieving suitable levels at the ulcer site.[2] The polymicrobial flora that is often present in the chronic wound may limit the use of topical antimicrobial agents because of the lack of sensitivity, potential toxicity to the host cellular components, and the potential for the development of resistant strains.[3]
The use of topical silver dressings has expanded in the chronic wound care setting due to the broad antimicrobial spectrum, low toxicity, and resistance profile of silver.[4] The recent introduction of silver-impregnated wound packing strips (SilverSeal® packing strips with X-Static®, Noble Biomaterials, Scranton, Pa) affords the clinician the ability to deliver the antimicrobial effect of silver using recommended treatment protocols.[5] Silver-impregnated packing strips are similar to existing packing products on the market in that they come in varying widths (Figure 1) to accommodate diverse clinical presentations. Unlike standard gauze, the strips are manufactured using nylon fiber that has been metalized with pure silver (Figures 2 and 3). The nylon resists absorption of wound fluid, enhancing the wicking effect and allowing the metalized silver fiber greater surface area to interact in the wound environment. The hydrophobic effect of the nylon fiber prevents saturation of the dressing, allowing it to function over longer periods of time, thereby decreasing dressing changes. The following case presentation represents the clinical use of this modality, resulting in resolution of the patient's ulcer in a shorter period of time than the usual 6 weeks stipulated for such treatment.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
_________________
Alpha
Visit Camp Greyhound at Awesomepaws!
Visit our Webstore
Offline
Profile
Alpha
Post subject: Re: Research on Colloidal Silver
PostPosted: Sat Feb 06, 2010 10:21 pm
Site Admin
Joined: Sun Jan 03, 2010 1:07 pm
Posts: 91
Location: Innisfil
Study Title:
Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia
Silver is the key to reducing pneumonia associated with breathing tubes. From Journal of the American Medical Association, Aug. 20, 2008. Full study at:
www.wellnessresources.com/studie ... _infection
People have long prized silver as a precious metal. Now, silver-coated endotracheal tubes are giving critically ill patients another reason to value the lustrous metal. In a study published in the Aug. 20, 2008 issue of the Journal of the American Medical Association, researchers at Washington University School of Medicine in St. Louis and the NASCENT Investigation Group, report that the silver-coated tubes led to a 36 percent reduction of ventilator-associated pneumonia (VAP).
VAP can strike up to 15 percent of people who are intubated to aid breathing and can cause death in an estimated 20 percent to 40 percent of those stricken.
“VAP is a relatively common infection and increasingly one caused by antibiotic-resistant bacteria,” says the study’s lead author, Marin H. Kollef, M.D., a Washington University pulmonary specialist at Barnes-Jewish Hospital. “There have been many attempts to prevent VAP, most of which have revolved around modifying hospital practices. The silver-coated endotracheal tube has an advantage in that it doesn’t require any additional effort by nurses, therapists and doctors, who may already be over burdened.”
Past efforts to prevent VAP included elevating the head of a patient’s bed, repeatedly checking ventilator tubing and emptying condensates, monitoring feeding to prevent reflux into the lungs, frequent handwashing and isolation of infected patients. The silver-coated endotracheal tube is structurally identical to a typical tube, so its adoption would not require any change in standard hospital procedures.
Studying 1,509 patients in 54 centers who were intubated for 24 hours or more, the research group found that 7.5 percent of those with uncoated tubes developed VAP. In comparison, 4.8 percent of those with silver-coated tubes developed VAP, a 36 percent reduction.
Kollef indicates that about 80 percent of patients are intubated for less than 10 days. Looking at just the first 10 days of intubation, the silver-coated tubes were associated with a 48 percent reduction in VAP, and when VAP occurred in patients with silver-coated tubes, it occurred later on average than in those with uncoated tubes.
Silver kills bacteria and yeast by sticking to the organisms’ enzymes, genetic material and other molecular components, preventing basic functions and interfering with reproduction. These organisms very rarely develop resistance to silver, and the metal has no known side effects in humans.
The new endotracheal tubes are coated with a silver-containing polymer, created by C.R. Bard Inc., that releases silver ions to the surface of the tubes. There, silver exerts a broad-spectrum antimicrobial effect, reduces adhesion of bacteria to the tube and blocks the formation of biofilms, communities of microorganisms that build up special protective structures on surfaces.
The number of antibiotic-resistant organisms is on the rise, making it ever more vital to prevent VAP and related infections, says Kollef, professor of medicine in the Division of Pulmonary and Critical Care Medicine. Even when an infection can be treated with antibiotics, it takes a physical toll on a patient, he notes.
Kollef, also medical director of the medical intensive care unit and of respiratory care services at Barnes-Jewish Hospital, says the silver-coated tubes are likely to be more expensive than uncoated tubes, but that the cost is easily recovered if the silver-coated tubes can reduce the number of VAP cases.
“I think this is just the beginning for this kind of technology,” Kollef says. “The silver-polymer coating will most likely be applied also to tracheostomy tubes and also become available for use in pediatric medicine. In the future, we could see other types of coatings with other functions placed on devices that come into contact with the body.”
###
Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Craven DE, Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI, Auger WR, Schinner R. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia. Journal of the American Medical Association, Aug. 20, 2008.
Funding from C.R. Bard Inc. supported this research. None of the study authors is associated with C.R. Bard Inc. Marin Kollef received speaker fees from the company.
NASCENT is the North American Silver-Coated Endotracheal Tube Investigation Group, which includes members at 11 institutions in the United States and one in Germany.
Study Information:
Marin H. Kollef, MD; Bekele Afessa, MD; Antonio Anzueto, MD; Christopher Veremakis, MD; Kim M. Kerr, MD; Benjamin D. Margolis, MD; Donald E. Craven, MD; Pamela R. Roberts, MD; Alejandro C. Arroliga, MD; Rolf D. Hubmayr, MD; Marcos I. Restrepo, MD; William Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia JAMA 2008 August 300(7):805-813.
Washington University School of Medicine, St Louis, Missouri.